Equity Rights Offering
Company: Core Scientific
What the later record shows
Delivered late · happened January 23, 2024
The $55 million Equity Rights Offering was oversubscribed and raised $55 million. It was consummated on the January 23, 2024 Effective Date, after the December 11, 2023 date.
“The Equity Rights Offering was oversubscribed and yielded proceeds of $55 million.”
2024-05-05 · Core Scientific 424B3 filed 2024-05-06 View cached copy (2026-08-31)Live source ↗
“the Company commenced an equity rights offering in accordance therewith on November 20, 2023, which was consummated on the Effective Date”
2024-05-05 · Core Scientific 424B3 filed 2024-05-06 View cached copy (2026-08-31)Live source ↗
“On January 23, 2024 (the “Effective Date”), the conditions to effectiveness of the Plan were satisfied and the Debtors emerged from the Chapter 11 Cases.”
2024-05-05 · Core Scientific 424B3 filed 2024-05-06 View cached copy (2026-08-31)Live source ↗
Checked October 10, 2026 against filings, releases and reporting published after the claim was made. Quotes are verbatim from the linked documents.
The claim, verbatim
Equity rights offering of $55 million in common shares of reorganized company priced at 30% discount to $1.5 billion enterprise value
Source (primary)
Core Scientific 8-K filed 2023-11-22 (SEC EDGAR, sec_filing)
View cached copy (2026-08-31)Live source ↗
Quote: “the Company is conducting an equity rights offering (the 'Equity Rights Offering') of common shares of the reorganized Company (the 'ERO Shares') in an aggregate amount of $55 million (the 'Rights Offering Amount'), at a price per share resulting from a 30% discount to the Plan Equity Value (as defined in the Plan), based on a total enterprise value $1.5 billion”
How we checked this
Checked on October 11, 2026. The cited source supports part of this claim, but not all of it.
The filing confirms the $55 million rights offering and the 30% discount, but it applies the discount to the Plan Equity Value, which is based on a $1.5 billion enterprise value, not to the enterprise value itself. Equity value and enterprise value are different measures.
Confirmed in the source:
- Core Scientific announced an equity rights offering of common shares of the reorganized company
- The equity rights offering is in an aggregate amount of $55 million
- The per-share price reflects a 30% discount
- The pricing is based on a total enterprise value of $1.5 billion
We could not confirm this from the cited source:
- The filing does not say the 30% discount is taken directly off the $1.5 billion enterprise value; it says the discount is to the Plan Equity Value, which is derived from that enterprise value
That does not mean it is false — only that this source does not establish it, as of the date above. If we find a source that settles it, we will re-check and update this page.
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1839341/000119312523282336/d557673d8k.htm) in full (29,507 characters, retrieved August 31, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Core Scientific 8-K filed 2023-11-22
Quote: “the Company is conducting an equity rights offering (the 'Equity Rights Offering') of common shares of the reorganized Company (the 'ERO Shares') in an aggregate amount of $55 million (the 'Rights Offering Amount'), at a price per share resulting from a 30% discount to the Plan Equity Value (as defined in the Plan), based on a total enterprise value $1.5 billion”
confirms Core Scientific 424B3 filed 2024-05-06
Quote: “The Equity Rights Offering was oversubscribed and yielded proceeds of $55 million.”